Intellia therapeutics revenue
NettetIntellia Therapeutics revenue from 2015 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or … Nettet6. mai 2016 · Intellia Therapeutics (NASDAQ: NTLA) is developing genome editing therapies that use CRISPR/Cas9 technology to cure genetic diseases with simple, targeted treatments. Use the CB Insights Platform to explore Intellia Therapeutics's full profile. ... Revenue $0000 View. About Intellia ...
Intellia therapeutics revenue
Did you know?
NettetIntellia Therapeutics, Inc. Healthcare Biotechnology USA statements Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. Nettet5. mai 2024 · Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2024.
Nettet10. apr. 2024 · Intellia Therapeutics GAAP EPS of -$1.40 misses by $0.04, revenue of $13.6M beats by $2.89M SA News Thu, Feb. 23 7 Comments Intellia Therapeutics Q4 2024 Earnings Preview Nettet8. apr. 2024 · The company's revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.09) EPS. On average, research analysts expect that Intellia Therapeutics, Inc. will post -5.81 earnings per share for the current year. Intellia Therapeutics Profile . 3 Genomics Stocks to …
Nettet14. apr. 2024 · Intellia Therapeutics shares last traded at $35.16, with a volume of 86,959 shares changing hands. ... The business’s revenue was up 5.4% compared to the …
Nettet23. feb. 2024 · Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 0% and 11.06%, respectively, for the quarter ended December 2024.
Nettet6. mai 2016 · Intellia Therapeutics's valuation in September 2015 was $274.68M. Intellia Therapeutics's latest post-money valuation is from May 2016. Sign up for a free trial to see Intellia Therapeutics's valuations in May 2016, November 2014 and more. Intellia Therapeutics's 2015 revenue was $6.04M. Intellia Therapeutics's most recent … breast cancer with lymph nodeNettet21. mar. 2024 · Intellia Therapeutics Financials Summary financials Revenue ( FY, 2024) $52.1M Net income ( FY, 2024) ($474.2M) Cash ( FY, 2024) $523.5M EBIT ( FY, 2024) ($458.2M) Enterprise value $3.0B Competitors and similar companies Ionis Pharmaceuticals Healthcare - Public 4D Molecular Therapeutics Healthcare - Public … breast cancer with mets to the boneNettet4. nov. 2024 · INTELLIA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2024 2024 … breast cancer with mets to liverNettet28. jul. 2024 · As of Q121, Intellia reported a cash position of $995m, down from $1.1bn in Q121. The company earned $11.3m of collaboration revenues in Q121, and made a net loss of $147m. Net loss in FY21 was... breast cancer with no symptomsNettet12 timer siden · Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA-2.79%) and Rivian Automotive ... Last year, Rivian reported $1.7 billion in revenue, ... breast cancer with mets to lung pet scanNettet13. apr. 2024 · Intellia Therapeutics Inc. (NASDAQ:NTLA) shares, rose in value on Thursday, ... Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $49.6 million, representing a decrease of -4.80% from the revenues reported in the last year’s results. breast cancer with micropapillary featuresNettet12 timer siden · Two stocks that analysts appear to be bullish on right now are Intellia Therapeutics (NTLA-2.79%) and Rivian Automotive ... Last year, Rivian reported $1.7 … breast cancer with no family history